Literature DB >> 23906603

Advances in the regulation of osteoclasts and osteoclast functions.

B F Boyce1.   

Abstract

Osteoclasts are derived from mononuclear hematopoietic myeloid lineage cells, which are formed in the bone marrow and are attracted to the bloodstream by factors, including sphingsine-1 phosphate. These circulating precursors are attracted to bone surfaces undergoing resorption by chemokines and other factors expressed at these sites, where they fuse to form multinucleated bone-resorbing cells. All aspects of osteoclast formation and functions are regulated by macrophage-colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), cytokines essential for osteoclast formation and expressed by a variety of cell types, including osteoblast lineage cells. Since the discovery of RANKL in the mid-1990s, mouse genetic and molecular studies have revealed numerous signaling pathways activated by RANKL and M-CSF. More recent studies indicate that osteoclasts and their precursors regulate immune responses and osteoblast formation and functions by means of direct cell-cell contact through ligands and receptors, such as ephrins and Ephs, and semaphorins and plexins, and through expression of clastokines. There is also growing recognition that osteoclasts are immune cells with roles in immune responses beyond mediating the bone destruction that can accompany them. This article reviews recent advances in the understanding of the molecular mechanisms regulating osteoclast formation and functions and their interactions with other cells in normal and pathologic states.

Entities:  

Keywords:  apoptosis; bone biology; bone remodeling/regeneration; chemokine(s); cytokine(s); osteoblast(s)

Mesh:

Substances:

Year:  2013        PMID: 23906603      PMCID: PMC3775372          DOI: 10.1177/0022034513500306

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  60 in total

Review 1.  Molecular mechanism of the life and death of the osteoclast.

Authors:  Sakae Tanaka; Tsuyoshi Miyazaki; Akira Fukuda; Toru Akiyama; Yuho Kadono; Hidetoshi Wakeyama; Shinjiro Kono; Shinya Hoshikawa; Masaki Nakamura; Yasushi Ohshima; Atsuhiko Hikita; Ichiro Nakamura; Kozo Nakamura
Journal:  Ann N Y Acad Sci       Date:  2006-04       Impact factor: 5.691

Review 2.  Transcriptional regulation by calcium, calcineurin, and NFAT.

Authors:  Patrick G Hogan; Lin Chen; Julie Nardone; Anjana Rao
Journal:  Genes Dev       Date:  2003-09-15       Impact factor: 11.361

3.  A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis.

Authors:  Paul D Miller
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-12       Impact factor: 5.346

4.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

Authors:  Hiroshi Takayanagi; Sunhwa Kim; Takako Koga; Hiroshi Nishina; Masashi Isshiki; Hiroki Yoshida; Akio Saiura; Miho Isobe; Taeko Yokochi; Jun-ichiro Inoue; Erwin F Wagner; Tak W Mak; Tatsuhiko Kodama; Tadatsugu Taniguchi
Journal:  Dev Cell       Date:  2002-12       Impact factor: 12.270

5.  NFAT and Osterix cooperatively regulate bone formation.

Authors:  Takako Koga; Yuichi Matsui; Masataka Asagiri; Tatsuhiko Kodama; Benoit de Crombrugghe; Kazuhisa Nakashima; Hiroshi Takayanagi
Journal:  Nat Med       Date:  2005-07-24       Impact factor: 53.440

6.  TSG-6 inhibits osteoclast activity via an autocrine mechanism and is functionally synergistic with osteoprotegerin.

Authors:  David J Mahoney; Catherine Swales; Nicholas A Athanasou; Michele Bombardieri; Costantino Pitzalis; Karolina Kliskey; Mohammed Sharif; Anthony J Day; Caroline M Milner; Afsie Sabokbar
Journal:  Arthritis Rheum       Date:  2011-04

Review 7.  Inhibition of cathepsin K for treatment of osteoporosis.

Authors:  Steven Boonen; Elizabeth Rosenberg; Frank Claessens; Dirk Vanderschueren; Socrates Papapoulos
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

8.  Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts.

Authors:  Takashi Nakamura; Yuuki Imai; Takahiro Matsumoto; Shingo Sato; Kazusane Takeuchi; Katsuhide Igarashi; Yoshifumi Harada; Yoshiaki Azuma; Andree Krust; Yoko Yamamoto; Hiroshi Nishina; Shu Takeda; Hiroshi Takayanagi; Daniel Metzger; Jun Kanno; Kunio Takaoka; T John Martin; Pierre Chambon; Shigeaki Kato
Journal:  Cell       Date:  2007-09-07       Impact factor: 41.582

9.  Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival.

Authors:  Susan A Krum; Gustavo A Miranda-Carboni; Peter V Hauschka; Jason S Carroll; Timothy F Lane; Leonard P Freedman; Myles Brown
Journal:  EMBO J       Date:  2008-01-24       Impact factor: 11.598

10.  The immunoreceptor tyrosine-based activation motif (ITAM) -related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints.

Authors:  Tania N Crotti; Anak A S S K Dharmapatni; Ekram Alias; Andrew C W Zannettino; Malcolm D Smith; David R Haynes
Journal:  Arthritis Res Ther       Date:  2012-11-12       Impact factor: 5.156

View more
  117 in total

1.  The NOD-scid IL2rγnull Mouse Model Is Suitable for the Study of Osteoarticular Brucellosis and Vaccine Safety.

Authors:  Omar H Khalaf; Sankar P Chaki; Daniel G Garcia-Gonzalez; Thomas A Ficht; Angela M Arenas-Gamboa
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

Review 2.  Does TNF Promote or Restrain Osteoclastogenesis and Inflammatory Bone Resorption?

Authors:  Baohong Zhao
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

3.  Osteoprotegerin exposure at different stages of osteoclastogenesis differentially affects osteoclast formation and function.

Authors:  Hongyan Zhao; Jianhong Gu; Nannan Dai; Qian Gao; Dong Wang; Ruilong Song; Wei Liu; Yan Yuan; Jianchun Bian; Xuezhong Liu; Zongping Liu
Journal:  Cytotechnology       Date:  2015-06-05       Impact factor: 2.058

Review 4.  Regulation of cell differentiation by Eph receptor and ephrin signaling.

Authors:  David G Wilkinson
Journal:  Cell Adh Migr       Date:  2014       Impact factor: 3.405

5.  Def6 Restrains Osteoclastogenesis and Inflammatory Bone Resorption.

Authors:  Nikolaus Binder; Christine Miller; Masaki Yoshida; Kazuki Inoue; Shinichi Nakano; Xiaoyu Hu; Lionel B Ivashkiv; Georg Schett; Alessandra Pernis; Steven R Goldring; F Patrick Ross; Baohong Zhao
Journal:  J Immunol       Date:  2017-03-17       Impact factor: 5.422

6.  Demethoxycucumin protects MDA-MB-231 cells induced bone destruction through JNK and ERK pathways inhibition.

Authors:  Xiaofeng Shen; Xiaochen Sun; Hua Chen; Binjie Lu; Yuanyuan Qin; Chenxi Zhang; Guoqiang Liang; Jiangping Wang; Pengfei Yu; Li Su; Qihan Ma; Yuwei Li
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-05       Impact factor: 3.333

7.  Adenosine A2A receptor (A2AR) stimulation modulates expression of semaphorins 4D and 3A, regulators of bone homeostasis.

Authors:  Aránzazu Mediero; Tuere Wilder; Lopa Shah; Bruce N Cronstein
Journal:  FASEB J       Date:  2018-02-02       Impact factor: 5.191

8.  Deletion of ferroportin in murine myeloid cells increases iron accumulation and stimulates osteoclastogenesis in vitro and in vivo.

Authors:  Lei Wang; Bin Fang; Toshifumi Fujiwara; Kimberly Krager; Akshita Gorantla; Chaoyuan Li; Jian Q Feng; Michael L Jennings; Jian Zhou; Nukhet Aykin-Burns; Haibo Zhao
Journal:  J Biol Chem       Date:  2018-05-03       Impact factor: 5.157

9.  Netrin-1 is a critical autocrine/paracrine factor for osteoclast differentiation.

Authors:  Aránzazu Mediero; Bhama Ramkhelawon; Miguel Perez-Aso; Kathryn J Moore; Bruce N Cronstein
Journal:  J Bone Miner Res       Date:  2015-05       Impact factor: 6.741

Review 10.  Chronic kidney disease and osteoporosis: evaluation and management.

Authors:  Paul D Miller
Journal:  Bonekey Rep       Date:  2014-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.